

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jacobson Pharma Corporation Limited

雅各臣科研製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code : 2633)

POSITIVE PROFIT ALERT

This announcement is made by Jacobson Pharma Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Directors**”) of the Company (the “**Board**”) wishes to inform shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary review of the unaudited consolidated management accounts of the Group for the year ended 31 March 2023 and the information currently available to the Board, the Group expects to record an increase of not less than 40% in the consolidated profit attributable to equity shareholders of the Company for the year ended 31 March 2023 as compared to that for the year ended 31 March 2022.

The increase was attributable to the gradual easing of pandemic-related restrictive measures in the Mainland China, Hong Kong and Macau, which (a) facilitated the resumption of medical consultation visits in both public and private sectors in Hong Kong, thus boosting the demand for essential drugs and specialty medicines for chronic diseases; and (b) heightened retail spending sentiment and overall sales demand of the Group’s products in the branded healthcare segment. This uplift in sales demand, alongside cost savings from operating leverage, coupled with the subsidies from the Hong Kong Government pertinent to the Employment Support Scheme, resulted in a notable increase in profit for the year ended 31 March 2023. Thanks to the scalable production capacities and target-oriented product development capabilities, the Group will vigorously pursue the growth strategies and thereby fortifying its strong market position.

As at the date of this announcement, the consolidated results of the Group for the year ended 31 March 2023 have not yet been finalised. The information contained in this announcement is only based on a preliminary assessment by the Board with reference to unaudited consolidated management accounts of the Group for the year ended 31 March 2023 and the information currently available to the Board. Such information has not been reviewed and confirmed by the auditors of the Company, and may be subject to adjustments. Further details of the Group's performance will be disclosed in the annual results announcement of the Company for the year ended 31 March 2023 in accordance with the Listing Rules, which is expected to be published on 15 June 2023.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Jacobson Pharma Corporation Limited
YU Chun Kau
Company Secretary

Hong Kong, 1 June 2023

As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek (also as Chairman and Chief Executive Officer), Mr. Yim Chun Leung and Ms. Pun Yue Wai as executive Directors, Professor Wong Chi Kei, Ian as non-executive Director, and Dr. Lam Kwing Tong, Alan, Mr. Young Chun Man, Kenneth and Professor Lam Sing Kwong, Simon as independent non-executive Directors.